安徽医科大学学报2017，Vol.52Issue(2)：252-255,4.DOI:10.19405/j.cnki.issn1000-1492.2017.02.023
131 I治疗分化型甲状腺癌伴肺转移的疗效及影响因素分析
Analysis of the efficacy and influence factors of 131 I therapy for lung metastases of differentiated thyroid carcinoma
摘要
Abstract
Objective To analyze the efficacy, influence factors and side effects of 131 I therapy for lung metastases of differentiated thyroid carcinoma ( DTC ) . Methods 49 patients with lung metastases of DTC who received 131 I treatment were retrospectively analyzed. Influence factors included patients′age, gender, cumulative doses, patho-logical classification, times of lung metastases by 131 I imaging, 131 I uptake pattern, Tg levels before treatment, cer-vical lymph node metastases and so on. Statistical methods included t test,χ2 test and Logistic regression analysis. Meantime, the side effects were observed during the 131 I treatment and follow-up period. Results The rates of par-tial response and invalidity of 131 I treatment DTC with lung metastases were 63. 3%( 31/49 ) and 36. 7%( 18/49 ) respectively. Univariate analysis showed that:age(t=4. 194, P<0. 001), Tg levels before treatment(t=3. 632, P<0. 05), Chest X-ray and(or) CT finding(χ2 =7. 385, P<0. 05), other distant metastases(χ2 =8. 586, P<0. 05), times of lung metastases by 131I imaging(χ2 =8. 077,P<0. 05) were the factors influencing outcome of 131I treatment. Logistic regression analysis showed that the influence factors included age, Tg levels before treatment and other distant metastases. 131 I treatment had no significant effect on hematopoietic function and liver function, but salivary gland function of some patients was impaired. Conclusion 131 I therapy is effective and safe for lung metastases of DTC, and the younger, the significant decrease of Tg levels before treatment and only lung metastases indicate a well prognosis.关键词
分化型甲状腺癌/肺转移/131I治疗Key words
differentiated thyroid carcinoma/lung metastases/131 I therapy分类
医药卫生引用本文复制引用
刘伯元,张然,金晓毛,姚晓波,邵小红,卞岍雨,刘学公..131 I治疗分化型甲状腺癌伴肺转移的疗效及影响因素分析[J].安徽医科大学学报,2017,52(2):252-255,4.基金项目
安徽省卫生厅医学科研课题(编号:13zc019) （编号:13zc019）
